Chinese guideline for the diagnosis and treatment of childhood obstructive sleep apnea (2020)

Introduction

Childhood obstructive sleep apnea (OSA) is a disorder of breathing during sleep characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction (obstructive apnea) that disrupts normal ventilation during sleep and normal sleep patterns in children. OSA is one of the most serious sleep-disordered breathing (SDB) diseases in children. Because of its high prevalence and serious long-term complications, increasing numbers of families are affected by OSA. In 2012, the American Academy of Pediatrics (AAP) clinical practice guidelines reported that the prevalence of pediatric OSA was 1.2%–5.7%; in 2010, the prevalence of pediatric OSA in Hong Kong, China was 4.8%. In contrast to OSA in adults, the main cause of upper airway obstruction in children is adenoid and/or tonsil hypertrophy. Obesity, craniofacial malformation, neuromuscular diseases, and other factors may also contribute to the onset of pediatric OSA. Without timely diagnosis and effective intervention, pediatric OSA can lead to a series of serious complications, such as maxillofacial dysplasia, behavioral abnormalities, learning disabilities, growth restriction, neurocognitive impairment, endocrine metabolic disorders, hypertension, and pulmonary hypertension; it can also increase the risk of cardiovascular events in adulthood. Therefore, early detection and early diagnosis of pediatric OSA, as well as early intervention to correct this problem, are important considerations for improving patient prognosis.

There have been some controversies in the clinical diagnosis and treatment of pediatric OSA in China, which have restricted clinical diagnosis and treatment strategies, while hindering progress regarding diagnosis and treatment. The diagnosis and treatment of pediatric OSA is increasingly hampered by the absence of multi-
disciplinary cooperation and guidelines. The numbers of pediatric OSA diagnosis and treatment guidelines and expert consensuses are very limited, both in China and worldwide.\textsuperscript{1,2,5,9-13} The draft guideline for diagnosis and treatment of pediatric obstructive sleep apnea hypopnea syndrome issued in 2007 was mainly established on the basis of expert consensus.\textsuperscript{1} In the past 10 years, there has been a lack of multi-disciplinary evidence-based diagnosis and treatment guidelines for pediatric OSA in China. Thus, evidence-based clinical practice guidelines are urgently needed. The purpose of the present guideline is to standardize the clinical diagnosis and treatment decision-making concerning pediatric OSA in China, provide scientific evidence for the diagnosis and treatment of pediatric OSA, promote multi-disciplinary integration, guide clinical practice for relevant medical staff, and ensure the use of a scientific approach for management of pediatric OSA.

**Target population**

This guideline is suitable for children aged 1–18 years with obstructive sleep apnea related to adenoid and/or tonsil hypertrophy, or related to obesity. The guideline is not applicable to children with central sleep apnea syndrome or hypoventilation syndrome. Moreover, they are not applicable to children with OSA who exhibit the following comorbidities: Down syndrome, severe craniofacial malformation, neuromuscular disease, chronic lung disease, sickle cell disease, metabolic disease, and/or laryngomalacia.

**Users**

This guideline is expected to be used by clinicians, nurses, technicians, and relevant teaching and scientific research staff engaged in sleep respiratory disease-related work in hospitals at all levels.

**Definitions of relevant terms**

The judgment of sleep events is consistent with the standard interpretation of children’s sleep respiratory events formulated by the American Academy of Sleep Medicine (AASM).\textsuperscript{14} The interpretation and definition are as follows:

1. Obstructive apnea: ≥ 90% reduction in airflow for at least two respiratory cycles, accompanied by respiratory efforts throughout the event.
2. Central apnea: ≥ 90% reduction in airflow for at least 20 s; or with event-related arousal or oxygen desaturations of ≥ 3% for at least two respiratory cycles; or heart rate reduction to ≤ 50 beats/min for at least 5 s; or heart rate < 60 beats/min for at least 15 s in at least two respiratory cycles (only for infants < 1 year of age). Each of these is accompanied by loss of chest and abdominal effort throughout the event.

3. Mixed apnea: ≥ 90% reduction in airflow for at least two respiratory cycles, beginning without effort and concluding with inspiratory effort.
4. Hypopnea: ≥ 30% reduction in airflow, accompanied by event-related arousal or oxygen desaturations of ≥ 3%, for at least two respiratory cycles.
5. Apnea hypopnea index (AHI): average number of apnea and hypopnea events per hour during sleep.
6. Obstructive apnea hypopnea index (OAHI): average number of obstructive apnea, mixed apnea, and hypopnea events per hour during sleep.
7. Obstructive apnea index (OAI): average number of obstructive apnea events per hour during sleep.

**TABLE 1** List of abbreviations

| Abbreviations | Full terms |
|---------------|------------|
| AAP           | American Academy of Pediatrics |
| AASM          | American Academy of Sleep Medicine |
| ASA           | Australasian Sleep Association |
| AH1           | Apnea hypopnea index |
| AI            | Arousal index |
| ATS           | American Thoracic Society |
| AUROC         | Area under receiver operating characteristics curve |
| AMSTAR2       | A measure tool to assess systematic reviews-second edition |
| AGREE-II      | Appraisal of Guidelines for Research and Evaluation II |
| BMI           | Body mass index |
| CI            | Confidence interval |
| CPAP          | Continuous positive airway pressure |
| ERS           | European Respiratory Society |
| GPS           | Good practice statement |
| GRADE         | Grading of Recommendations Assessment, Development and Evaluation |
| ICSD          | International Classification of Sleep Disorders |
| ICSD-3        | International Classification of Sleep Disorders-Third Edition |
| LSO2          | Lowest oxygen saturation |
| MAA           | Mandibular advancement appliance |
| MD            | Mean differences |
| NLR           | Negative likelihood ratio |
| NPPV          | Non-invasive positive pressure ventilation |
| OAHI          | Obstructive apnea hypopnea index |
| OAI           | Obstructive apnea index |
| ODI           | Oxygen desaturation index |
| OSA           | Obstructive sleep apnea |
| OSA-18        | Obstructive sleep apnea 18-item quality of life questionnaire |
| OR            | Odds ratio |
| PLR           | Positive likelihood ratio |
| PSG           | Polysomnography |
| PSQ           | Pediatric sleep questionnaire |
| RCT           | Randomized controlled trial |
| RME           | Rapid maxillary expansion |
| RR            | Risk ratio |
| SDB           | Sleep-disordered breathing |
| SMD           | Standardized mean difference |
| WHO           | World Health Organization |
| WMD           | Weighted mean difference |
8. Oxygen desaturation index (ODI): average number of oxygen desaturation events of $\geq 3\%$ per hour during sleep.

**Recommendation**

The guideline includes 11 clinical questions and 24 recommendations for diagnosis and treatment, summarized in Table 2. Grading of evidence quality and recommendation strength is described in Table 3 by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).

**Clinical questions**

**Diagnosis questions**

Clinical question 1: In the diagnosis of pediatric OSA, what clinical symptoms and signs should be considered? 

Recommendations:

Regarding symptoms, the presence and frequency of snoring should be considered first. Snoring $\geq 3$ nights/week merits clinical attention (1A).

Further considerations should include sleep apnea, mouth breathing, laborious breathing, restless sleep, enuresis, daytime drowsiness, attention deficit/hyperactivity, and poor academic performance (1B). For young children, mouth breathing, repeated arousal, and emotional and behavioral abnormalities should receive clinical attention (GPS).

Regarding physical signs, adenoid hypertrophy, tonsil hypertrophy, adenoid face, and obesity should be considered (1B).

Whether based on a single symptom/sign or a combination of multiple symptoms and signs, pediatric OSA cannot be reliably diagnosed without the use of polysomnography (PSG). Additional diagnostic methods are recommended to improve the accuracy of diagnosis (1B).

Evidence summary:

The guideline working group performed a qualitative analysis of 21 studies that described OSA-related symptoms and signs in children; these 21 studies included seven guidelines and three systematic reviews. The results were as follows: all 21 studies reported snoring symptoms (six reported snoring frequencies and four studies reported snoring frequencies of $3$ nights/week). Additionally, attention deficit/hyperactivity, apnea, daytime sleepiness, and weight loss or gain were frequently reported, as were tonsil hypertrophy, adenoid hypertrophy.

Two systematic reviews assessed the accuracy of clinical history and/or signs for diagnosis of OSA, compared with the accuracy of PSG.\textsuperscript{15,16} Twelve original studies ($n = 1058$ patients) were included in a systematic review published in 2004\textsuperscript{15}; these included six prospective cohort studies, four retrospective case series, one cross-sectional study, and one case-control study, with sample sizes ranging from 12 to 326 cases. There was significant heterogeneity among PSG-based diagnostic criteria, such as AHI events (apnea or hypopnea) and their ranges (1–15 episodes per hour). A meta-analysis based on data from 10 studies suggested that the positive predictive value (PPV) was 55.8% (95% confidence interval [CI]: 42.1–69.6); the sensitivities and specificities of the clinical evaluation parameters were $\leq 65\%$ in all studies.\textsuperscript{15} Methodological heterogeneity and clinical heterogeneity were evident among studies, but the results of the included studies were relatively consistent. The systematic review findings suggested that, compared with PSG, clinical symptoms and signs are not effective for diagnosis of OSA. Furthermore, 10 diagnostic tests ($n = 1525$ patients) were included in a systematic review published in 2012.\textsuperscript{16} Heterogeneity was observed among the included studies. Only six studies defined AHI $> 1$/h as the threshold for diagnosis of pediatric OSA; no study described identification of symptoms and signs, nor did any study assess the consistency between observers. The systematic review results suggested that tonsil hypertrophy and snoring were highly sensitive parameters, but were not specific for OSA; daytime sleepiness, apnea, and nocturnal dyspnea were highly specific parameters, but were not sensitive for OSA. The sensitivity and specificity ranges of the seven assessed models (using combinations of symptoms and signs) were $4\%$–$94\%$ and $28\%$–$99\%$,\textsuperscript{16} respectively. Area under the receiver operating characteristic curve (AUROC) results indicated that symptoms and signs have poor diagnostic ability for pediatric OSA. Therefore, compared with PSG, neither a single symptom/sign nor a combination of multiple symptoms and signs can effectively diagnose pediatric OSA.\textsuperscript{15,16} Other diagnostic models are needed to improve the accuracy of diagnosis. Another systematic review assessed the diagnostic value of clinical history and physical examination, compared with PSG, in pediatric SDB\textsuperscript{17}; its conclusions were consistent with the findings of previous analyses.

Justification:

This recommendation is based primarily on the evidence of symptoms and signs that occur with greater frequency. To formulate the working group’s expert opinions based on the results of expert interviews and guidelines, some symptoms not included in the recommendations but observed in clinical practice (e.g., foaming at the mouth, prone position/head back/sitting/over-extension of the neck, and the three depression signs) are also worthy of clinical attention; these should be evaluated in clinical examinations, in combination with the above recommendations and individual child’s performance. In addition, comprehensive assessment of upper airway
TABLE 2 Summary of questions and recommendations

| Questions                                                                 | Recommendations                                                                                                                                 |
|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| **Diagnosis questions**                                                   |                                                                                                                                                 |
| 1. In the diagnosis of pediatric obstructive sleep apnea (OSA), which clinical symptoms and signs should be considered? | Regarding symptoms, the presence and frequency of snoring should be considered first. Snoring ≥ 3 nights/week merits clinical attention (1A). Further considerations should include sleep suffocation, apnea, mouth breathing, laborious breathing, restless sleep, enuresis, daytime drowsiness, attention deficit/hyperactivity, and poor academic performance (1B). For young children, mouth breathing, repeated arousal, and emotional and behavioral abnormalities should receive clinical attention (GPS). Regarding physical signs, adenoid hypertrophy, tonsil hypertrophy, adenoid face, and obesity should be considered (1B). Whether based on a single symptom/sign or a combination of multiple symptoms and signs, pediatric OSA cannot be diagnosed without the use of polysomnography (PSG). Additional diagnostic methods are recommended to improve the accuracy of diagnosis (1B). |
| 2. In PSG, what are the key indicators with direct diagnostic significance for pediatric OSA, and what is the recommended threshold for diagnosis? | PSG is the standard diagnostic method for pediatric OSA. Obstructive apnea hypopnea index (OAHI) > 1/h is recommended as the threshold value for the early identification of children with sleep-disordered breathing who require intervention; additionally, apnea hypopnea index, obstructive apnea index, and lowest oxygen saturation (LSaO₂) are important assessments for the evaluation of pediatric OSA (1A). |
| 3. How should the severity of OSA be graded?                              | The severity of OSA is recommended to be graded based on PSG findings. The suggested grades are as follows (2B): mild, 1 h < OAHI ≤ 5 h; moderate, 5 h < OAHI ≤ 10 h; severe, OAHI > 10 h. The severity of OSA is not recommended to be graded on the basis of tonsil size (1B). |
| 4. What is the diagnostic value of portable or alternative diagnostic tools (e.g., pulse oximeter)? | PSG is recommended for the diagnosis of pediatric OSA (1A). For hospitals with limited access to PSG, the use of clinically proven portable sleep monitoring equipment (e.g., pulse oximeter) is recommended. Other clinical information such as medical history, physical examination, and questionnaire results should be integrated for comprehensive diagnosis. If necessary, patients should be referred to medical institutions where PSG monitoring is available (2C). |
| 5. What is the diagnostic value of pediatric OSA-related questionnaires or scales, such as the pediatric sleep questionnaire (PSQ) and the obstructive sleep apnea 18-item quality of life questionnaire (OSA-18)? | The PSQ and OSA-18 alone are not recommended to be used as diagnostic tools for pediatric OSA. A combination of medical history, physical examination, and sleep monitoring findings are recommended to increase the specificity of questionnaire-based diagnosis (2D). |
| **Treatment questions**                                                   |                                                                                                                                                 |
| 6. What are the surgical indications for adenoidectomy and/or tonsillectomy in children with OSA? | When children are diagnosed with moderate or severe OSA and clinical findings are consistent with adenoid and/or tonsil hypertrophy, adenoidectomy and/or tonsillectomy is recommended for children without surgical contraindications (1B). For children diagnosed with OSA whose clinical findings are not consistent with adenoid and/or tonsil hypertrophy, a comprehensive assessment of the upper airway (including the oral and nasal cavities) is required; further treatments are recommended (GPS). |
| 7. What are the risk factors for postoperative persistent OSA in children? | Critical evaluation of postoperative persistent OSA is recommended for obese children; supplementary treatments should be administered when necessary (1B). Children with OSA and the following characteristics are recommended to undergo postoperative monitoring: age < 3 years at the time of surgery; asthma and/or nasal diseases (e.g., allergic rhinitis or sinusitis); OAHI > 10/h and/or lowest oxygen saturation < 80%; family history of OSA (2B). |
| 8. What are the efficacy and safety of nasal corticosteroids and leukotriene receptor antagonists in children with OSA? | For children with mild to moderate OSA, adenoid and tonsil evaluation should be performed. Until this evaluation has been completed, nasal corticosteroids or oral montelukast sodium are recommended to reduce sleep apnea events and improve symptom scores. Moreover, regular follow-up is recommended to evaluate efficacy and possible adverse reactions (1B). For children who are receiving NPPV or oral montelukast sodium, nasal corticosteroids combined with oral montelukast sodium are recommended for children with mild or moderate OSA. Regular follow-up is recommended to evaluate efficacy and possible adverse reactions (2D). For children with OSA who do not respond favorably to medication or who experience recurrence after withdrawal, other treatments are recommended on the basis of comprehensive assessments of the upper airway (GPS). |
| 9. What are the indications, efficacy, and long-term adverse reactions of non-invasive positive pressure ventilation (NPPV) for children with OSA? | For children with OSA who have surgical contraindications without adenoid and/or tonsil hypertrophy, as well as children with persistent OSA after adenoidectomy and/or tonsillectomy, combined with non-surgical treatments, NPPV is recommended as an effective treatment after comprehensive assessments of the upper airway (1B). NPPV is recommended as an alternative or a perioperative complementary treatment option for children with severe OSA (GPS). For children who are receiving NPPV, adjustment of ventilator parameters under PSG monitoring is recommended. Periodic evaluation of ventilator parameters is also recommended (GPS). The application of NPPV to children with OSA may result in mild adverse reactions, such as nasal symptoms, optic irritation, and skin damage. The long-term use of NPPV may cause craniofacial abnormalities; thus, regular evaluation is recommended (GPS). |
| 10. What is the efficacy and safety of oral appliance therapy in the treatment of pediatric OSA? | Oral evaluation and oral appliance treatment are recommended for children with OSA who may exhibit oral and maxillofacial development problems, especially those with OSA who may not exhibit adenoid or tonsil hypertrophy, as well as those with persistent postoperative OSA, those who are inoperable, and those who are unable to tolerate NPPV treatment (GPS). After oral evaluation, children with OSA who require oral appliance treatment should receive maxillary expansion or mandibular anterior guidance according to the type of tooth and jaw deformity, as well as the site of airway obstruction. Maxillary arch expansion is effective for treatment of mild to moderate OSA, especially in children with middle palatal suture before bony healing (2D). Mandibular leading orthodontics is effective for children with mild to severe OSA. Treatment is recommended before puberty. Long-term treatment (> 6 months) is better than short-term treatment (1B). |
| 11. What is the efficacy of weight loss in obese children with OSA?        | For overweight or obese children with OSA, clinicians should recommend behavioral and dietary interventions to control weight (1D). |
obstruction in pediatric OSA should be emphasized, including the presence of allergic rhinitis, nasal septum deviation, nasopharyngeal mass, laryngeal space occupation, or tumor. Children’s symptoms and signs are an important basis for the initial diagnosis of pediatric OSA, but their diagnostic accuracy is low. Diagnosis of pediatric OSA solely based on a single symptom/sign or a combination of symptoms and signs is not recommended; additional diagnostic tools should be used. In addition, this recommendation is based on the 2019 recommendations of the European Respiratory Society (ERS), which distinguish among symptoms and signs according to age. For example, the main symptoms in younger children include snoring, mouth breathing, restless sleep, and abnormal emotional behavior, while the main symptoms in older children include snoring, apnea, daytime sleepiness, attention deficit/hyperactivity, learning difficulties, and memory decline.

Clinical question 2: In PSG, what are the key indicators with direct diagnostic significance for pediatric OSA, and what is the recommended threshold for diagnosis?

Recommendation:

PSG is the standard diagnostic method for pediatric OSA. OAH > 1/h is recommended as the threshold value for the early detection of children with SDB who require intervention; additionally, AHI, OAI, and lowest oxygen saturation (LSaO2) are important assessments for the evaluation of pediatric OSA (1A).

Evidence summary:

The 2012 AAP Guideline included a systematic review of 10 diagnostic studies (from 12 publications) since 2002, all of which used standard PSG for diagnosis of pediatric OSA.2 However, the diagnostic criteria were inconsistent among studies. The key indicators for OSA diagnosis included AHI and OAI; the AHI thresholds were 1/h, 3/h, and 5/h. A systematic review of 10 studies was published in 201316; the results showed that the diagnostic thresholds used for diagnosis of pediatric OSA by PSG were inconsistent, such that six studies used AHI > 1/h and two studies used AHI > 5/h.

In a 2016 Chinese diagnostic trial (n = 1115 patients),18 PSG was applied to children who met the diagnosed criteria of American Thoracic Society (ATS) (AHI > 5/h or OAI > 1/h) and who were between the International Classification of Sleep Disorders (ICSD) and ATS thresholds (OAI ≥ 1/h, while AHI ≤ 5/h and OAI ≤ 1/h), as well as children who met the ICSD criteria for primary snoring (OAI < 1/h). The mean and longest durations of obstructive apnea were significantly longer in children between ICSD and ATS thresholds than in the ICSD primary snoring group (P < 0.01); moreover, LSaO2 was lower in children between ICSD and ATS thresholds than in the primary snoring group (P < 0.05). Children between ICSD and ATS thresholds had obvious nocturnal symptoms, their daytime behavior was affected, and their PSG parameters were similar to those of children with OSA. Therefore, OAH ≥ 1/h should be regarded as the diagnostic threshold of pediatric OSA; this approach is more conducive to the early identification of children with SDB who require intervention. A 2005 cross-sectional study (n = 48 patients) explored the value of PSG in the differential diagnosis of snoring in children.19 The results showed that the mean SaO2, lowest SaO2, and the SaO2 < 95% times were significantly different between children with AHI < 1/h and those with AHI ≥ 5/h (P < 0.01), while there was no significant difference in snoring index or total number of snoring sounds; thus, AHI ≥ 1/h was more suitable for the diagnosis of OSA in children. A 2016 cross-sectional survey in China (n = 99 participants) analyzed the sleep-breathing parameters of healthy children.20 OAI and OAH were similar between children aged 3–5 years and those aged 6–14 years (OAI, 0.08 ± 0.12/h and 0.07 ± 0.14/h, respectively; OAH, 0.18 ± 0.21/h.

### TABLE 3 Grading of quality of evidence and strength of recommendation

| Category          | Description                                                                 |
|-------------------|----------------------------------------------------------------------------|
| Quality of evidence |                                                                             |
| High (A)          | We are very confident that the true effect lies close to that of the estimate of the effect. |
| Moderate (B)      | We are moderately confident in the effect estimate: the true effect is presumably close to the estimate of the effect, but it might be substantially different. |
| Low (C)           | Our confidence in the effect estimate is limited: the true effect maybe substantially different from the estimate of the effect. |
| Very low (D)      | We have very little confidence in the effect estimate: the true effect is presumably substantially different from the estimate of effect. |
| Strength of recommendation |                                                                             |
| Strong (1)        | Advantages of intervention considerably outweigh disadvantages, or disadvantages of intervention considerably outweigh advantages |
| Weak (2)          | Advantages of intervention may outweigh disadvantages, or disadvantages of intervention may outweigh advantages |
| Good practice statement (GPS) | Recommendations based on indirect evidence or expert opinion/experience |
and 0.19 ± 0.26/h, respectively); the 95% CI for OAHI in healthy children was < 1/h.

Justification:

This recommendation is based on available evidence, as well as the 2017 ERS Guideline.\textsuperscript{21} It is consistent with the International Classification of Sleep Disorders-Third Edition (ICSD-3) (Table 4).\textsuperscript{22} OAHI > 1/h was used as the diagnostic threshold for pediatric OSA. This recommendation emphasizes the importance of obstructive factors in the diagnosis of pediatric OSA. Central respiratory events in pediatric OSA are presumably associated with long-term obstructive apnea and hypoventilation. This recommendation is made with the presumption that obstructive factors constitute the root cause of pediatric OSA; these factors lead to a series of pathophysiological changes in children with OSA. Therefore, OAHI should be used as the main objective indicator for the diagnosis of OSA, rather than AHI.

Clinical question 3: How should the severity of OSA be graded?

Recommendations:

The severity of OSA is recommended to be graded based on PSG findings. The suggested grades are as follows (2B): mild, 1/h < OAHI ≤ 5/h; moderate, 5/h < OAHI ≤ 10/h; severe, OAHI > 10/h.

The severity of OSA is not recommended to be graded on the basis of tonsil size (1B).

Evidence summary:

A 2011 systematic review (20 studies) assessed tonsil size and PSG value for pediatric OSA severity rating.\textsuperscript{25} The results showed an association between subjective tonsil size and OSA severity in 11 of the 20 studies, but revealed no association in the remaining nine studies. No difference was observed between high quality (score 3.22) and low quality (score 2.36) studies. Thus, a weak correlation was recorded between the severity of objective OSA and the size of children’s tonsils. High-quality studies showed no association between subjective tonsil size and objective OSA severity.

Some studies used clinical parameters to assess the severity of pediatric OSA. The results suggested no correlation between tonsil size and AHI or ODI.\textsuperscript{26} In preschoolers, a weak correlation has been observed between adenoid size and OSA severity; adenoid hypertrophy is considered the main cause of OSA in preschoolers with normal weight.\textsuperscript{27} For OSA severity classification, standards have been inconsistent among studies, but most are based on obstructive AHI values of 5/h, 10/h, or 15/h.\textsuperscript{28–30} Some studies have referred to SpO\textsubscript{2} and total sleep time.\textsuperscript{29}

In 2014, the Australasian Sleep Association Guideline recommended OAHI as the standard for classification of pediatric OSA severity.\textsuperscript{23} OAHI < 1.2/h was regarded as normal, 1.2/h ≤ OAHI < 5/h as mild abnormality, 5/h ≤ OAHI < 10/h as moderate abnormality, and 10/h ≤ OAHI < 30/h as severe abnormality. The 2007 Draft Guideline of the Chinese Medical Association used AHI or OAI as the criteria for OSA severity classification in children.\textsuperscript{1} Specifically, 5/h ≤ AHI ≤ 10/h or 1/h ≤ OAI ≤ 5/h and LSaO\textsubscript{2} saturation between 0.85 and 0.91 were considered indicative of mild abnormality, while 10/h < AHI ≤ 20/h or 5/h < OAI ≤ 10/h and LSaO\textsubscript{2} saturation between 0.75 and 0.84 were considered indicative of moderate abnormality; AHI > 20/h or OAI > 10/h and LSaO\textsubscript{2} saturation < 0.75 were considered indicative of severe abnormality.

Justification:

The purpose of the severity rating in this recommendation is to guide the assessment of prognostic risk for pediatric OSA: “mild OSA”, “moderate OSA”, and “severe OSA” are established as indicated in Table 4. Notably, existing systematic reviews of tonsil size did not show an association with AHI or ODI. Uniform grading standards of OSA severity are not available; previous studies have

| Country/Region | Formulating institutions | Year | Mild | Moderate | Severe | Extreme severe | Reference type |
|----------------|--------------------------|------|------|----------|--------|---------------|----------------|
| America        | American Academy of Sleep Medicine (AASM)\textsuperscript{22} | 2014 | OAHI: ≥1 | – | – | – | ICSD-3 |
| Europe         | European Respiratory Society (ERS)\textsuperscript{21} | 2017 | OAHI: ≥1–5 | OAHI: >5–10 | OAHI: >10 | – | Systematic review |
| Australasia    | Australasian Sleep Association\textsuperscript{23} | 2014 | OAHI: ≥1.2–5 | OAHI: ≥5–10 | OAHI: ≥10–30 | OAHI: >30 | Guideline |
| America        | American Society of Anesthesiologists\textsuperscript{24} | 2014 | AHI: 1–5 | AHI: 6–10 | AHI: >10 | – | Guideline |
| China          | Editorial Board of Chinese Journal of Otolaryngology Head and Neck Surgery, Otolaryngology Branch of Chinese Medical Association\textsuperscript{1} | 2007 | AHI: ≥5–10 or OAI: ≥21–5, LSaO\textsubscript{2}: 0.85–0.91 | AHI: >10–20 or OAI: >5–15, LSaO\textsubscript{2}: 0.75–0.84 | AHI: >20 or OAI: >10, LSaO\textsubscript{2}: < 0.75 | – | Guideline |

The units of OAHI, AHI and OAI are episodes/h. OAHI, obstructive apnea hypopnea index; AHI, apnea hypopnea index; OAI, obstructive apnea index; LSaO\textsubscript{2}, lowest oxygen saturation; ICSD-3, International Classification of Sleep Disorders-Third Edition; –, not applicable.
used values established in systematic reviews, other original studies, and published guidelines (Table 4). This recommendation uses 1/h < OAHI ≤ 5/h, 5/h < OAHI ≤ 10/h, and OAHI > 10/h as criteria for pediatric OSA severity rating. Long-term follow-up of children with OSA is difficult; there remains a lack of cohort studies, both in China and globally, regarding the correlation between graded diagnosis of pediatric OSA and long-term effects on diseases and complications (e.g., changes in cognition, metabolism, cardiopulmonary function, and cardiovascular health). Therefore, long-term follow-up and cohort analysis of children with OSA is an important future research goal.

Clinical question 4: What is the diagnostic value of portable or alternative diagnostic tools (e.g., pulse oximeter)?

Recommendations:

PSG is recommended for the diagnosis of pediatric OSA (1A).

For hospitals with limited access to PSG, the use of clinically proven portable sleep monitoring equipment (e.g., pulse oximeter) is recommended. Other clinical information such as medical history, physical examination, and questionnaire results should be integrated for comprehensive diagnosis. If necessary, patients should be referred to medical institutions where PSG monitoring is available (2C).

Evidence summary:

The systematic review produced by the Steering Group included 13 studies (n = 1633 patients). Of these 13 studies, seven used pulse oximeters (n = 1450 patients) and six used portable sleep monitoring devices (n = 183 patients). Seven studies did not provide original data for descriptive analysis; of the remaining six studies, three used pulse oximeters (n = 1019 patients) and three used watch-PAT devices (n = 114 patients). The combined sensitivity and specificity of OSA diagnosis using PSG were 75.0% (95% CI: 53.0%–89.0%) and 88.0% (95% CI: 70.0%–96.0%), respectively. The positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 6.2 (95% CI: 2.5–15.4) and 0.3 (95% CI: 0.1–0.7), respectively. The cumulative area under the receiver operating characteristic curve was 0.89 (95% CI: 0.86–0.91, P = 0.000).

In 2013, a systematic review of 33 studies (n = 1064 patients; AMSTAR2 = 7.5) reported a comparison of PSG with 40 other diagnostic methods. One pulse oximeter and two portable sleep monitoring devices were compared with PSG (sample size ranged from 21 to 57) in studies published from 1995 to 2003. Two studies (both using OSA diagnostic criteria AHI > 1/h) reported sensitivities of 66.7% and 100%, whereas they reported specificities of 66.7% and 62.5%.

Justification:

This recommendation continues to support PSG as a standard diagnostic method for pediatric OSA. However, standard PSG monitoring involves equipment limitations, as well as a complex technical process, requirement for specialized personnel, and high cost. Therefore, clinicians are recommended to use pulse oximeters and other portable monitoring equipment to support the findings of clinical examinations when PSG monitoring is unavailable. Objective assessment and preliminary diagnosis of sleep breathing characteristics are recommended to obtain more objective diagnostic evidence before initiation of clinical treatment in children with OSA; this approach supports comprehensive assessment and individual treatment. It is also consistent with the 2012 AAP Guideline and 2014 Australasian Sleep Association Guideline. If use of the above portable equipment reveals severe OSA, affected patients should be referred to a medical institution with the ability to perform PSG, prior to treatment. In addition, the retrieval evidences of the above recommendations of the is not limited to the equipment type of evidence, but sleep monitoring III–IV level equipment have various kinds and the clinical question mainly focused on simple alternative diagnostic tools such as the diagnostic accuracy of pulse oximeter. For the method of pulse oxygen monitoring, the McGill oxygen score (Table 5) could be used. For children who do not meet the the McGill oxygen score (e.g., children with SaO2 < 0.90 fewer than three times and more than three clusters of SaO2 decrease events, or children with SaO2 < 0.90 more than three times and stable baseline SaO2 > 0.95), PSG is recommended to facilitate a clear diagnosis.

| Score   | Implication | Standard | Other                      |
|---------|-------------|----------|----------------------------|
|         | No. of drops in SaO2 <0.90 | No. of drops in SaO2 <0.85 | No. of drops in SaO2 <0.80 | Baseline: stable (<3 clusters of desaturation) and >0.95 |
| MOS 1   | Normal study/inconclusive    | <3       | 0                          | 0                          | Three or more clusters of desaturation events |
| MOS 2   | Mild        | ≥3       | ≤3                         | 0                          | Three or more clusters of desaturation events |
| MOS 3   | Moderate    | ≥3       | >3                         | ≤3                         | Three or more clusters of desaturation events |
| MOS 4   | Severe      | ≥3       | >3                         | >3                         | Three or more clusters of desaturation events |

A cluster of desaturations was defined as ≥ 5 desaturations in a 10–30 minute period. Each score was required to meet the criteria for “No. of drops in SaO2” and “Others”. |
Clinical question 5: What is the diagnostic value of pediatric OSA-related questionnaires or scales, such as the pediatric sleep questionnaire (PSQ) and the obstructive sleep apnea 18-item quality of life questionnaire (OSA-18)?

Recommendation:

The PSQ and OSA-18 alone are not recommended to be used as diagnostic tools for pediatric OSA. A combination of medical history, physical examination, and sleep monitoring findings are recommended to increase the specificity of questionnaire-based diagnosis (2D).

Evidence summary:

In total, eight studies were included in a comparison of diagnostic accuracy between OSA-related questionnaires or scales and PSG (OSA-18: four studies, n = 1047 patients; PSQ: four studies, n = 472 patients). The PSQ questionnaire here specifically refers to the sub-questionnaire of sleep-related breathing disorders, which cover the three major symptoms of pediatric OSA: sleep snoring, drowsiness, and hyperactivity. Four studies did not provide original data for descriptive analysis. The remaining four studies revealed the following respective combined sensitivity, specificity, PLR, NLR, and AUROC values for PSQ (n = 307 patients) and OSA-18 (n = 743 patients) in the diagnosis of pediatric OSA: 77% (95% CI: 55%–90%), 61% (95% CI: 38%–80%), 2.0 (95% CI: 1.2–3.3), 0.38 (95% CI: 0.19–0.76), and 0.75 (95% CI: 0.71–0.78, P = 0.000).

A systematic review (AMSTAR2 = 10) published in 2014 investigated the accuracy of PSG in diagnosis of SDB in children by comparing multiple physical examinations and questionnaires among four subgroups: questionnaire, questionnaire + physical examination, questionnaire + physical examination + other diagnostic methods, and physical examination + other diagnostic methods.17 Of the 11 included diagnostic tests, three assessed PSQ vs. PSG (n = 102 patients), PSQ + physical examination vs. PSG (n = 61 patients), and OSA-18 + physical examination + other diagnostic methods vs. PSG (n = 527 patients). The results suggested that the diagnostic accuracy of questionnaire-based assessment was insufficient to replace PSG or other objective examinations as an independent approach.

Justification:

The 2012 AAP Guideline2 and 2014 Australasian Sleep Association Guideline32 clearly emphasize the importance of clinical symptoms and questionnaires/scales in the preliminary diagnosis of OSA. For quantitative assessments of clinical symptoms, questionnaires are simple, convenient, and non-invasive. In 2011, a total of 6404 sleep assessment tools were available worldwide, including 183 children’s sleep disorders questionnaire and scales. Unfortunately, few screening tools have been evaluated for reliability and validity.34 In terms of the questionnaires that have been scientifically validated and widely used in China, this recommendation mainly advocates the use of two questionnaires, PSQ and OSA-18. The PSQ has been translated into Portuguese,35 Spanish,36 Chinese37,38 and other versions; its reliability and validity have been confirmed. As a current approach to investigate the quality of life in children with OSA, the OSA-18 has been widely used; this questionnaire covers five dimensions (18 items): sleep disorder, physical symptoms, emotional distress, daytime conditions, and the degree of influence on guardians. However, current evidence suggests that the diagnostic accuracy of the questionnaire is low; thus, it cannot replace PSG or other objective examinations as an independent diagnostic tool. This questionnaire should be used in combination with other clinical diagnosis tools, including PSG (if necessary).

Treatment questions

Clinical question 6: What are the surgical indications for adenoidectomy and/or tonsillectomy in children with OSA?

Recommendations:

When children are diagnosed with moderate or severe OSA and clinical findings are consistent with adenoid and/or tonsil hypertrophy, adenoidectomy and/or tonsillectomy is recommended for children without surgical contraindications (1B).

For children diagnosed with OSA whose clinical findings are not consistent with adenoid and/or tonsil hypertrophy, a comprehensive assessment of the upper airway (including the oral and nasal cavities) is required; further treatments are recommended (GPS).

Evidence summary:

The results of qualitative studies are made as follows: 1) Seventy-seven studies were retrieved regarding surgical indications in children with OSA; these included 10 guidelines (recommendations are shown above), 3 systematic reviews, and 64 original studies. 2) The systematic reviews and original studies mainly discussed surgical efficacy, surgical methods, and complications related to adenoidectomy and/or tonsillectomy in children with OSA (inclusion criteria were pediatric OSA with adenoid and/or tonsil hypertrophy). 3) Two studies had a minimum age of 1 year in patients who underwent surgery, while 13 studies had a minimum age of 2 years; the remaining studies had a minimum age of 3 years. 4) The shortest course of OSA in children ranged from 3 to 6 months in patients who underwent surgery.

Justification:
Tonsillectomy and/or adenoidectomy are currently first-line treatments for pediatric OSA, especially in children with moderate to severe OSA, following comprehensive assessments of the upper airway (including nasal, nasopharyngeal, oropharyngeal, laryngopharyngeal, and laryngeal cavities) and systemic detailed assessments and examination of the upper airway who do not exhibit tonsil and/or adenoid hypertrophy, and postoperative dehydration.

Anesthesia complications, postoperative respiratory failure, hemorrhage, palatopharyngeal insufficiency, and nasopharyngeal stenosis; minor risks include pain and postoperative dehydration. For children with OSA who do not exhibit tonsil and/or adenoid hypertrophy, detailed assessments and examination of the upper airway (e.g., oral, nasal, and laryngeal cavities) and systemic problems (e.g., neuromuscular diseases) are needed, as are assessments of obstructions and associated factors. If necessary, consultations from relevant departments should be arranged to assist in diagnosis and treatment.

Clinical question 7: What are the risk factors for postoperative persistent OSA in children?

Recommendations:

Critical evaluation of postoperative persistent OSA is recommended for obese children; supplementary treatments should be administered when necessary (1B).

Children with OSA and with the following characteristics are recommended to undergo postoperative monitoring: age ≤ 3 years at the time of surgery; asthma and/or nasal diseases (e.g., allergic rhinitis or sinusitis); OAHI ≥ 10; obesity (OR = 3.77, 95% CI: 1.57–9.05, P = 0.01). On the basis of distinct diagnostic criteria, this review established three subgroups: AHI ≥ 1/h (OR: 3.77, 95% CI: 1.57–9.05, P < 0.01), AHI ≥ 2/h (OR: 7.96, 95% CI: 2.76–22.92, P < 0.01), and AHI ≥ 5/h (OR: 8.73, 95% CI: 4.50–16.94, P < 0.01). The results suggested that preoperative obesity is a risk factor for postoperative persistent OSA. 2) Overweight (three studies, n = 224 patients). Overweight children had no risk for postoperative persistent OSA, compared with normal-weight children (OR: 0.76, 95% CI: 0.20–2.96, P = 0.70). 3) Accompanying diseases (one study, n = 85 patients). The asthma (OR: 1.31, 95% CI: 0.50–3.41, P = 0.58) and allergic rhinitis (OR: 0.96, 95% CI: 0.39–2.39, P = 0.93) were not associated with elevated risk of postoperative persistent OSA. 4) Family history of diseases. SDB (two studies, n = 194 patients) (OR: 1.35, 95% CI: 0.62–2.91, P = 0.45), allergy (two studies, n = 194 patients) (OR: 2.24, 95% CI: 0.95–5.28, P = 0.07), and obesity (one study, n = 84 patients) (OR: 1.03, 95% CI: 0.20–5.32, P = 0.98) were not associated with elevated risk of postoperative persistent OSA. These findings suggested that obesity constitutes a risk factor for postoperative persistent OSA in pediatric patients.

A systematic review in 2015 (51 studies, n = 3413 patients, one randomized controlled trial [RCT] and other case studies or non-RCTs, AMSTAR2 = 7.5) showed that the postoperative AHI significantly decreased by 12.4-
fold in children with OSA, compared with preoperative AHI; however, LSaO₂ was enhanced in these children. ⁴¹
The overall rate of postoperative AHI < 1/h was 51% (obese vs. non-obese vs. undifferentiated obesity groups: 34% vs. 49% vs. 56%), while the overall rate of AHI < 5/h was 81% (obese vs. non-obese vs. undifferentiated obese groups: 61% vs. 87% vs. 84%). Meta-regression analysis showed that the rate of postoperative AHI persistence was positively correlated with preoperative AHI and body mass index (BMI) Z-score. These results suggested that surgery can significantly improve sleep parameters in children with OSA, especially for non-obese patients. Postoperative persistent OSA is likely to occur in children with severe OSA and obesity.

Justification:
Notably, obesity is an independent risk factor for pediatric OSA. The current clinical evidence also suggests that obesity is a risk factor for postoperative persistent OSA. PSG or portable or simple alternative diagnostic tools can be used to evaluate postoperative persistent OSA. Supplementary treatments should be considered as appropriate, including non-invasive positive pressure ventilation (NPPV), orthodontic therapy, and weight loss. Current evidence indicates that accompanying diseases (e.g., asthma and allergic rhinitis) and family history of OSA do not increase the risk of postoperative persistent OSA. However, on the basis of existing guidelines and expert recommendations,²⁻⁴ clinicians should perform careful postoperative evaluation and airway management in children with OSA aged < 3 years, as well as those with accompanying diseases, severe OSA, hypoxemia, and/ or relevant family history. In addition, clinicians should perform comprehensive assessments of the upper airway in children with OSA, especially those whose disease severity (based on PSG assessment) is not consistent with adenoid and/or tonsil hypertrophy (i.e., children with adenoid and/or tonsil hypertrophy who do not exhibit frequent sleep apnea events, or those with frequent sleep apnea events who do not exhibit clinically significant adenoid and/or tonsil hypertrophy). About the treatment of complications related to postoperative persistent OSA in children, 2014 Australasian Sleep Association Guideline recommended that children with age < 3 years plus a co-morbidity or with very severe OSA (OAHI or ODI ≥ 30; or oxygen saturation nadir < 70%; or McGill oximetry score 4) should be monitored post-operatively in a hospital with an onsite intensive care unit and should be considered for closer monitoring. Children with very severe OSA and morbid obesity (BMI > 35 kg/m²) should have a planned post-operative intensive care unit admission.²³

For children with mild to moderate OSA, adenoid and tonsil evaluation should be performed. Until this evaluation has been completed, nasal corticosteroids or oral montelukast sodium are recommended to reduce sleep apnea events and improve symptom scores. Moreover, regular follow-up is recommended to evaluate efficacy and possible adverse reactions (1B).

Regarding combination therapy, following adenoid and tonsil evaluation, nasal corticosteroids combined with oral montelukast sodium are recommended for children with mild or moderate OSA. Regular follow-up is recommended to evaluate efficacy and possible adverse reactions (2D).

Evidence summary:
A systematic review was conducted, which included four, three, and two RCTs to evaluate the respective efficacy and safety of nasal corticosteroids, leukotriene receptor antagonists (e.g., montelukast sodium), and combined usage of these two drugs in children with OSA. The review included four RCTs (n = 204 patients) regarding the use of nasal corticosteroids in children with OSA. 1) The results of three RCTs (n = 142 patients) suggested that nasal corticosteroids reduced OAHI (standardized mean difference [SMD]: −3.34, 95% CI: −4.66 to −2.01, P < 0.0001) and ODI (SMD: −2.18, 95% CI: −3.86 to −0.50, P = 0.10), compared with placebo; there were no significant differences between the two groups in arousal index (SMD: −1.32, 95% CI: −4.61 to 1.97, P = 0.43) or LSaO₂ (SMD: 2.06, 95% CI: −2.44 to 6.57, P = 0.37). Of the included studies, two reported adenoid morphology; the findings in one of these two studies suggested that nasal corticosteroids reduced adenoid morphology in children with OSA, compared with placebo, while the findings in the other study suggested no differences. 2) One RCT (n = 62 patients) constituted a randomized crossover trial of nasal budesonide, compared with placebo (normal saline), for 6 weeks. Data concerning the comparison between groups after random allocation were not reported; thus, that study was analyzed separately. All 62 patients in the RCT completed the first phase of the randomized crossover trial; 19 patients (five in the drug group and 14 in the placebo group) then withdrew from the trial. The results of the RCT suggested that nasal budesonide reduced the AHI in 48 patients (30 in the first phase and 18 in the second phase) who completed treatment, compared with 32 patients in placebo group in the first phase. 3) In terms of adverse reactions, two studies reported nausea, vomiting, and diarrhea, while the remaining two studies reported no events. 4) A meta-analysis revealed obvious clinical heterogeneity in three studies with respect to types

Clinical question 8: What are the efficacy and safety of nasal corticosteroids and leukotriene receptor antagonists in children with OSA?

Recommendations:
of nasal corticosteroids (mometasone furoate nasal spray in two studies and fluticasone propionate nasal spray in one study), number of medicine, and duration (4 weeks, 6 weeks, and 4 months).

The systematic review also included three RCTs (n = 187 patients) regarding the use of montelukast sodium in children with OSA.\(^1\) Compared with placebo (non-intervention group), the results of two RCTs (n = 103 patients) suggested that montelukast sodium reduced OAH (SMD: −0.99, 95% CI: −1.40 to −0.58, \(P < 0.00001\)), ODI mean difference [MD]: −2.83, 95% CI: −3.86 to −1.79, \(P < 0.00001\)], and AI (SMD: −1.02, 95% CI: −1.47 to −0.57, \(P < 0.00001\]), while elevating LSaO\(_2\) (MD: 4.07, 95% CI: 2.27–5.88, \(P < 0.00001\)). The results of one RCT (n = 46 patients) showed that montelukast sodium relieved symptoms of snoring (SMD: −1.84, 95% CI: −2.53 to −1.14, \(P < 0.00001\)) and mouth breathing (SMD: −1.22, 95% CI: −1.85 to −0.59, \(P = 0.0002\)). The results of another RCT (n = 57 patients) suggested that there was no significant difference in tonsil morphology (SMD: −0.20, 95% CI: −0.46 to 0.06, \(P = 0.14\)) and adenoid morphology (SMD: −0.58, 95% CI: −1.19 to 0.03, \(P = 0.06\)) between the two groups. The methodological quality in both RCTs was high, but the sample size was limited. 2) The results of another RCT (n = 84 patients; montelukast sodium combined with routine treatment vs. routine treatment) suggested that montelukast sodium reduced AHI (MD: −1.62, 95% CI: −2.63 to −0.61, \(P = 0.002\)), while improving LSaO\(_2\) (MD: 2.53, 95% CI: 0.88–4.18, \(P = 0.003\)) and reducing adenoid morphology (RR: 0.15, 95% CI: 0.04–0.64, \(P = 0.01\)).

The review included two RCTs (n = 234 patients) regarding combined use of nasal corticosteroids and leukotriene receptor antagonists (montelukast sodium) in children with OSA.\(^1\) The results of two RCTs (n = 169 patients; nasal corticosteroids combined with oral montelukast sodium vs. nasal corticosteroids) suggested that there was no significant difference in improving AHI between the two groups (SMD: −0.48, 95% CI: −2.24 to 1.28, \(P = 0.59\)), although the combination group showed better LSaO\(_2\) (SMD: 1.11, 95% CI: 0.79–1.44, \(P < 0.0001\)), compared with the nasal corticosteroids group. One study reported no adverse reactions and another did not include outcome indicators. The results of one RCT (n = 122 patients; nasal corticosteroids combined with oral montelukast vs. oral montelukast) suggested that the combination treatment improved LSaO\(_2\) (MD: 1.20, 95% CI: 0.34–2.06, \(P = 0.006\)) and reduced adenoid morphology (MD: −0.02, 95% CI: −0.03 to −0.01, \(P = 0.002\)) compared with oral montelukast, while there was no significant difference in AHI improvement (MD: 0.31, 95% CI: −0.07 to 0.69, \(P = 0.11\)) between the two groups. Of these two RCTs, one (n = 195 patients; oral montelukast vs. nasal corticosteroids [four patients were lost to follow-up] vs. nasal corticosteroids combined with oral montelukast [eight patients were lost to follow-up]) mainly compared efficacy before and after treatment in three subgroups; it showed significant efficacy among the three groups in indicators including AHI, LSaO\(_2\), snoring, and mouth breathing (but not tonsil morphology) after treatments, compared with baseline, although no comparison was made between groups. 2) Notably, there were no detailed descriptions of allocation concealment in these two studies, and no mention of blinding method; moreover, they had different extents of loss to follow-up.

Five systematic reviews compared drug treatments in children with OSA.\(^{41,46-49}\) A Cochrane systematic review in 2011 verified the efficacy and safety of anti-inflammatory drugs for children with OSA (AMSTAR2 = 14).\(^{46}\) Two RCTs (n = 87 patients) evaluated nasal corticosteroids, while one RCT evaluated montelukast sodium (only the abstract was published). 1) The first RCT (n = 25 patients) showed that a 6-week-regimen of fluticasone propionate nasal spray reduced AHI in children with mild to moderate OSA, compared with placebo (MD: −7.20, 95% CI: −13.96 to −0.44), whereas no significant difference was observed in LSaO\(_2\) (MD: −1.20, 95% CI: −5.06 to 2.66); moreover, no significant differences were recorded in tonsil morphology or clinical symptom scores reported by the patients’ parents (e.g., snoring, apnea, and daytime sleepiness). Data concerning long-term safety and efficacy remain unclear; that study had high methodological quality, but used a small sample size. 2) The other published RCT was a randomized crossover trial with a 6-week cycle (n = 62 patients); the findings suggested that budesonide nasal spray reduced AHI, compared with placebo. This study was not performed on the basis of random assignment, so the results should be interpreted cautiously. A systematic review in 2015 included two RCTs and one case-control trial (n = 105/27 patients; AMSTAR2 = 7.5).\(^{47}\) This review, based on single-group data comparison of 6-week nasal corticosteroids (fluticasone and budesonide) before and after treatment, suggested that nasal corticosteroids could reduce AHI in children with OSA (weighted mean difference [WMD]: 4.07, 95% CI: 0.00–8.14, \(P < 0.00001\)). Budesonide was confirmed to occasionally cause mild symptoms including epistaxis, diarrhea, and vomiting, but these did not lead to drug discontinuation. There were obvious methodological and clinical heterogeneities among the three studies; moreover, the randomly assigned drug group and controls were not compared. A systematic review in 2013\(^{48}\) (two RCTs, n = 76 patients; AMSTAR2 = 10.5) suggested that, in children with OSA, montelukast sodium reduced AHI (OAI > 1/h or AHI > 5/h) (MD: −2.06, 95% CI: −2.28 to −1.84, \(P < 0.00001\)), AI (MD: −4.18, 95% CI: −5.14 to −3.21, \(P < 0.00001\)), and apnea index (MD: −1.18, 95% CI: −1.28 to −1.08, \(P < 0.00001\)), compared with placebo; however, there was no difference in mean blood oxygen saturation (MD: 0.75, 95% CI: −0.32 to 1.83, \(P = 0.17\)) and no adverse events were reported.
A systematic review in 2018\(^6\) included six studies \((n = 668\) patients; one cross-sectional study, two prospective cohort studies, one retrospective cohort study, and two placebo-controlled RCTs) that investigated the efficacy of montelukast sodium for children with OSA. Among these studies, the results of two RCTs were consistent with the findings in the systematic review published in 2013.\(^48\) The remaining two studies (a prospective cohort study and a retrospective cohort study; \(n = 502\) patients) compared the efficacy of oral montelukast sodium combined with nasal corticosteroids before and after treatment; they revealed reduced AHI \((MD: -4.18, 95\% CI: -6.33 to -2.04, P < 0.0001)\) and LSAT \((MD: 4.76, 95\% CI: 4.46-5.06, P < 0.000001)\) after treatment. Four studies \((n = 511\) patients) included in the above systematic review reported adverse reactions. Three patients had mild nausea, headache, and epistaxis; no serious adverse reactions were reported. A reticular meta-analysis in 2017\(^50\) (seven RCTs, \(n = 499\) patients; AMSTAR2 = 7.5) showed that mometasone furoate \((WMD: 1.40, 95\% CI: 1.17–1.63)\), budesonide \((WMD: 3.50, 95\% CI: 3.34–3.66)\), fluticasone \((WMD: 7.20, 95\% CI: 5.26–9.14)\), and montelukast sodium \((WMD: 2.80, 95\% CI: 1.01–4.59)\) fully reduced AHI, compared with placebo; fluticasone had the greatest efficacy.

**Justification:**

Nasal corticosteroids and montelukast sodium are recommended for children with mild or moderate OSA who have adenoid and/or tonsil hypertrophy (especially those with adenoid hypertrophy), excluding other problems such as oral-maxillofacial defects and upper airway obstruction. In particular, nasal corticosteroids are recommended for children with OSA accompanied by rhinitis symptoms such as nasal congestion, runny nose, sneezing, and rhinolalia clausa. For children with moderate OSA and adenoid and/or tonsil hypertrophy, adenoidectomy and/or tonsillectomy remain first-line treatments. For children with surgical contraindications, those waiting for surgery, and those whose parents refuse surgery, the above drugs are recommended as conservative treatments. In terms of efficacy, the present systematic review suggested that nasal corticosteroids effectively reduced OAHI and ODI in children with OSA, while oral montelukast sodium reduced OAHI and improved symptom scores. In addition, there have been few high-quality RCTs to determine efficacy and adverse reactions related to the use of nasal corticosteroids combined with montelukast sodium; long-term follow-up data are limited. The efficacy of combined use of these drugs is an important research avenue concerning drug treatments for children with OSA and adenoid hypertrophy, consistent with the guidelines of the French Society of ear nose and throat and Head & Neck Surgery.\(^42\) On the basis of the above findings and instructions of these drugs, these drugs are recommended for use in children aged \(>2\) years. The current clinical studies are limited to short-term follow-up and lack normative long-term prospective analysis. Additionally, the clinical indications for drug withdrawal and conversion to surgery require further evidence-based analyses. Possible adverse reactions should be monitored during drug treatments (e.g., epistaxis, headache, diarrhea, nausea, and/or vomiting). Notably, some studies have shown that montelukast sodium might be associated with psychiatric symptoms including nightmares, aggressive behaviors, depression, and suicide. In 2019, the United States Food and Drug Administration stated that montelukast sodium might cause a risk of neurological/psychiatric events, including depression, self-mutilation, and suicide.\(^51\) Clinicians should immediately discontinue medication and refer patients to an appropriate specialist if such symptoms develop. Comprehensive assessments are required after courses of treatment have been completed. For children with OSA who exhibit no clinically significant improvements in symptoms, signs, and OAHI, as well as children who exhibit recurrence after drug withdrawal, clinicians should fully consider the etiology and re-evaluate obstructions of the upper airway (See recommendation 6).

**Clinical question 9: What are the indications, efficacy, and long-term adverse reactions of non-invasive positive pressure ventilation (NPPV) for children with OSA?**

**Recommendations:**

For children with OSA who have surgical contraindications without adenoid and/or tonsil hypertrophy, as well as children with persistent OSA after adenoidectomy and/or tonsillectomy, combined with non-surgical treatments, NPPV is recommended as an effective treatment after comprehensive assessments of the upper airway (1B).

NPPV is recommended as an alternative or a perioperative complementary treatment option for children with severe OSA (GPS).

For children who are receiving NPPV, adjustment of ventilator parameters under PSG monitoring is recommended. Periodic evaluation of ventilator parameters is also recommended (GPS).

The application of NPPV to children with OSA may result in mild adverse reactions, such as nasal symptoms, optic irritation, and skin damage. The long-term use of NPPV may cause craniofacial abnormalities; thus, regular evaluation is recommended (GPS).

**Evidence summary:**

For this recommendation, two RCTs were retrieved regarding the efficacy and adverse reactions of positive pressure ventilation in the treatment of children with OSA; the RCTs could not be combined due to clinical heterogeneity. One study \((n = 70\) patients) was a randomized, double-blind controlled trial (continuous
positive airway pressure [CPAP] combined with surgery vs. surgery alone); its findings suggested that combined treatment reduced AHI (MD: −6.80, 95% CI: −10.62 to −2.98, \( P = 0.0005 \)), but did not provide information regarding adverse reactions or complications. The study also indicated that other indicators were significantly altered in the CPAP group; these included improvements in the blood oxygenation and Epworth Sleepiness Score (ESS), as well as reductions in the partial pressure of carbon dioxide and apnea duration. The findings of study (\( n = 67 \) patients) with a lower methodological quality (CPAP combined with routine treatment vs. routine treatment alone) suggested that CPAP significantly reduced AHI while enhancing \( \text{LSaO}_2 \).

Justification:

The application of NPPV to children with OSA should be based on comprehensive airway assessments to identify upper airway obstructions. However, drug-induced sleep endoscopy and magnetic resonance imaging are not recommended for routine examinations. The use of NPPV should be combined with individual conditions and clinical requirements, and there is no restriction or recommendation regarding the age of application. CPAP is considered an effective alternative treatment for children with OSA; thus, it is used as an important supplementary treatment for children with severe OSA during the perioperative period,\(^2\) as well as a temporary intervention for special children with OSA who are waiting for craniofacial surgery.\(^2\) Children with OSA who are using CPAP or other noninvasive ventilation treatments must complete pressure titration during sleep monitoring; the parameters should be re-evaluated regularly. In 2016, the expert consensus of Sleep Cooperative Group, Respiratory Group, Chinese Pediatrics Society, Editorial Board of the Chinese Journal of Practical Pediatrics\(^3^) reported that NPPV for children with OSA must be monitored and followed up for an extended period in a specialized medical center with pediatric NPPV to avoid or ensure timely identification of mask-related craniofacial abnormalities.

Clinical question 10: What is the efficacy and safety of oral appliance therapy in the treatment of pediatric OSA?

Recommendations:

Oral evaluation and oral appliance treatment are recommended for children with OSA who may exhibit oral and maxillofacial development problems, especially those with OSA who may not exhibit adenoid or tonsil hypertrophy, as well as those with persistent postoperative OSA, those who are inoperable, and those who are unable to tolerate NPPV treatment (GPS).

After oral evaluation, children with OSA who require oral appliance treatment should receive maxillary expansion or mandibular anterior guidance according to the type of tooth and jaw deformity, as well as the site of airway obstruction. Maxillary arch expansion is effective for treatment of mild to moderate OSA, especially in children with middle palatal suture before bony healing (2D). Mandibular leading orthodontics is effective for children with mild to severe OSA. Treatment is recommended before puberty. Long-term treatment (> 6 months) is better than short-term treatment (1B).

Evidence summary:

A meta-analysis in 2017 (including one RCT, nine case series, two case reports, and five case-control studies, \( n = 314 \) patients) investigated the use of rapid maxillary expansion (RME) for the treatment of pediatric OSA in children with high palatal arch or upper palate stenosis (i.e., transverse maxillary hypoplasia).\(^4\) The results showed that AHI decreased (MD: \(-4.84\), 95% CI: \(-8.47\) to \(-1.21\)) and \( \text{LSaO}_2 \) increased (MD: 5.78, 95% CI: 1.99–9.58). A systematic review in 2016 investigated rapid arch expansion for the treatment of pediatric OSA (\( n = 215 \) patients).\(^5\) The results suggested that RME could reduce AHI by a mean of 6.86 h (\( P < 0.0001 \)). In 2017, the results of a systematic review (five non-randomized controlled trials, \( n = 137 \) patients) suggested that rapid arch expansion could reduce AHI in children with OSA (SMD: 3.24, 95% CI: 0.34–6.15).\(^6\) A systematic review published in 2019 included a descriptive analysis of six studies; the results suggested that rapid arch expansion achieved maxillary and nasal lateral wall widening by 3.4 mm and 3.3 mm, respectively; these distances decreased to 2.8 mm and 2.2 mm after puberty.\(^7\) For arch expansion performed before puberty, the width of the upper alveolar seat and maxilla increased continuously and steadily during long-term follow-up; for the arch expansion performed after puberty, only the nasal lateral wall increased by 1.3 mm, compared with the control group, while the maxillary bony width did not increase. A 2016 Cochrane systematic review (quasi-RCT, \( n = 23 \) patients; AMSTAR2 = 15) compared personalized oral appliances with nonintervention treatment in children with OSA (AHI > 1).\(^8\) The results suggested that orthodontic intervention could reduce AHI in children with mild OSA (risk ratio [RR]: 0.39, 95% CI: 0.20–0.76, \( P = 0.0061 \)), while improving buccal respiration (RR: 0.16, 95% CI: 0.04–0.59, \( P = 0.0060 \)), nasal stuffiness (RR: 0.18, 95% CI: 0.05–0.69, \( P = 0.013 \)), and habitual snoring (RR: 0.18, 95% CI: 0.06–0.55, \( P = 0.0028 \)). However, there remains insufficient evidence to support the use of orthodontic treatment for OSA.

A systematic review in 2019 (including three RCTs, one crossover RCT, and three non-randomized controlled trials, \( n = 188 \) patients; AMSTAR2 = 12) evaluated the efficacy of mandibular advancement appliance (MAA) in the treatment of pediatric OSA.\(^9\) Two of the high-quality RCTs (\( n = 34 \) patients) showed that, compared
with placebo intervention, children with OSA in the MAAs group had lower AHI (MD: −1.75, 95% CI: −2.07 to −1.44) and higher LSaO2 (RR: 3.4, 95% CI: 0.9–5.9, P = 0.007). Scores on the Children’s Sleep Questionnaire and Quality of Life and Behavior improved, whereas there was no difference in ODI between the two groups. Sensitivity analysis included other low-quality studies; the pooled results were consistent with those of the above two high-quality studies. With MAA treatment, subgroup analysis showed that the AHI values in patients with mild OSA (AHI < 5), moderate OSA (5 < AHI < 10), and severe OSA (AHI > 10) were reduced by 50% (1.72/3.5), 57% (4.27/7.5) and 76% (10.69/14.08), respectively. Furthermore, MAA treatment could reduce AHI in the younger group (age, 6–9.5 years) and the older group (age, 9.5–13 years). The results suggested that MAAs could be used to treat OSA in children < 13 years of age. However, minimal post-puberty data are available.

Justification:

Orthodontics is an important supplementary treatment for children with OSA. For clinical otolaryngologists and respiratory physicians, it is important to clarify the indications for orthodontic evaluation and establish the approach of diagnosis and treatment combined with comprehensive stomatology treatment. During orthodontic treatment, it is particularly necessary for children with OSA to complete regular orthodontic follow-up; sleep monitoring should be carried out systematically for 3–6 months after discontinuation of treatment.42 For children with OSA who exhibit mouth breathing, oral muscle function training can be used as adjuvant therapy.

Clinical question 11: What is the efficacy of weight loss in obese children with OSA?

Recommendation:

For overweight or obese children with OSA, clinicians should recommend behavioral and dietary interventions to control weight (1D).

Evidence summary:

A systematic review in 2016 (n = 359 participants, including 163 patients with OSA; AMSTAR2 = 5.5) included 16 studies, among which four investigated two types of weight loss (using descriptive analysis): surgical (two retrospective studies, n = 260 participants, including 117 patients with OSA) and behavioral (two prospective studies, n = 99 participants, including 46 patients with OSA).46 In the surgical weight loss analysis, among 34 obese children (obesity defined as BMI ≥ 95th percentile) included in one study, 19 obese children with OSA (obesity defined as BMI > 40 kg/m²) underwent gastric bypass surgery. Among 10 patients who underwent postoperative follow-up, the mean BMI values before and after surgery were 60.8 ± 11.07 kg/m² and 41.6 ± 9.5 kg/m², respectively. The mean AHI decreased from 9.1 to 0.65 (P < 0.01) and the rate of OSA persistence was 10% (1/10). In another study, 98 obese children with OSA (obesity defined as BMI > 40 kg/m²) underwent laparoscopic condom gastrectomy and the rate of OSA persistence was 18% (18/98); no BMI or AHI information were recorded before and after surgery. Two other studies investigated behavioral weight loss (i.e., dietary restriction, physical activity, and psychological support) as an intervention for obese children with OSA (in one study, obesity was defined as BMI > 40 kg/m²). The AHI was reduced by weight loss intervention; OSA persistence rates were 38% (8/21) and 33% (3/9), respectively.

A case series study in 2018 (n = 24 patients) investigated the efficacy of physical exercise combined with dietary changes as weight loss intervention for children with OSA (n = 14 patients; AHI ≥ 2).45 Subgroup analysis showed no significant change in AHI after 9 months of weight loss intervention.

Justification:

For obese children with OSA, clinicians should recommend weight control,1,2 in addition to other treatments. Normal weight standards for school-age children are provided in the “People’s Republic of China Health Industry Standard (WS/T 586-2018) Overweight and Obesity Screening for School-age Children and Adolescents”,67 and in the “Clinical Intervention Guideline for Obese Children” published by the European Endocrine Society and Pediatric Endocrinology Society.63 However, there is currently a lack of high-quality research concerning the efficacy of weight loss therapy on OSA in children, because the available studies mainly constitute case series of patients with very high BMI (> 40 kg/m²), older age (>15 years), and limited data.

Guideline development process and methods

Guideline development methodology

The guideline was developed in accordance with the most recent standards of the Institute of Medicine,24 and the development methodology was based on the development process described in the 2015 World Health Organization (WHO) Handbook for Guideline Development and related methodological standards,65 as well as the second version of the Appraisal of Guidelines for Research and Evaluation II (AGREE-II).66 The guideline was reported based on the Reporting Items for Practice Guidelines in Healthcare.67

Proposal and registration of the guideline

The guideline was registered on the International Practice Guidelines Registry Platform (http://guidelines-registry.
The proposal of guideline has been published in the 1st issue of Chinese Journal of Evidence-based Medicine in 2020.

**Guideline working group**

The guideline working group was established in July 2018, consisting of four groups: steering group, guideline development group, evidence synthesis and evaluation group, and external review group. The working group was composed of clinical experts, guidance methodology experts, evidence-based medicine experts, clinical epidemiology experts, health statistics experts, editors of professional journals, and experts from other fields. Clinical experts included otolaryngologists, head and neck surgeons, respiratory medicine experts, stomatologists, chronic disease management experts, and developmental behavior experts; notably, pediatricians comprised 78% of the clinical experts. Patients and guardian preferences were considered during the selection of outcome indicators and the formation of recommendations.

The methodological support and guidance for this guideline were jointly provided by the Evidence-based Medicine Center of Lanzhou University/Chinese GRADE Centre, the Peking University Evidence-based Medicine Center/Peking University School of Public Health, and the Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children’s Hospital, Capital Medical University.

**Statement of conflict of interest**

All participants involved in the formulation of the guideline, including the steering group, the guideline development working group, evidence synthesis and evaluation group, and the external review group have completed the required declaration of interest forms. All participants declare no financial and non-financial conflicts of interest directly related to this guideline.

**Collection and selection of clinical questions and outcomes**

The list of clinical questions and outcomes was formulated following the published OSA-related guidelines and systematic reviews. Then the duplicated questions and outcomes were removed and several questions and outcomes were combined if necessary. During the selection of clinical questions, two rounds of Delphi surveys were conducted and a face-to-face consensus meeting was held. The core members of guideline development group, repeatedly discussed and identified 11 clinical questions relevant to this guideline, including five diagnostic clinical questions and six treatment clinical questions. The clinical questions were constructed by clinical experts and methodologists on the basis of the Population, Intervention, Comparison, and Outcome (PICO) principle. The formulation of the list of outcomes was based on the retrieved literature and in-depth interviews, and considering the patients/guardians' preferences and values. After various degrees of discussion, the guideline development group agreed upon outcomes for use in this guideline.

**Search, synthesis, and evaluation of evidence**

This guideline was formulated following retrieval and evaluation of OSA, adenoidectomy, and/or tonsillectomy-related guidelines, as well as OSA-related systematic reviews/meta-analyses at different stages of topic and scope determination; evidence synthesis and evaluation was also performed. During the development of systematic reviews, the corresponding original studies and data analyses were retrieved and evaluated.

**Inclusion and exclusion criteria**

Inclusion criteria: 1) Participants: children diagnosed with OSA-obstructive sleep apnea syndrome /obstructive sleep apnea-hypopnea syndrome, aged 1 to 18 years; 2) Intervention and comparative measures: no limitation; 3) Outcomes: no limitation; 4) Study types: Searching guidelines and consensuses related to OSA and adenoidectomy and/or tonsillectomy; Searching OSA-related systematic reviews/meta-analyses; Searching relevant primary research.

Exclusion criteria: patients with primary snoring, central apnea or hypopnea syndrome, and children with OSA complicated by other congenital or severe diseases, such as Down syndrome, craniofacial deformities, neuromuscular diseases (e.g., cerebral palsy), chronic lung disease, sickle cell disease, metabolic disease, and/or laryngomalacia. Intervention measures involving traditional Chinese medicine (e.g., Chinese herbal medicine, proprietary Chinese medicine, and/or acupuncture). Documents and data published in multiple articles or formats.

**Data sources and search strategies**

Data sources include 1) Database search: English databases include PubMed, Excerpt Medica Database (EMBASE), the Cochrane Library; Chinese databases including China Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), VIP and Wanfang databases. The retrieval time is from the inception of the database to September 2019. 2) Related resources of the guide: NGC (http://www.ngc.gov), NICE (https://www.nice.org.uk/guidance), GIN (https://www.g-i-n.net), WHO (http://www.who.int/publications/guidelines/en/), Uptodate (https://www.uptodate.com/contents/search) and Medical Maitong. 3) PROSPERO (International prospective register of systematic reviews) registration platform for systematic review/meta-analysis of related retrieval resources. 4) Resources related to clinical trials: WHO International Clinical Trial Registry Platform. 5) Supplementary search: investigation of
OSA-related research references and Baidu academic supplementary investigation.

Main search terms included three aspects: OSA, children's population, and study type. The PubMed search strategy is shown in Table 6.

Evidence screening and data extraction

Evidence screening and data extraction were performed independently by at least two reviewers, in accordance with the above inclusion and exclusion criteria. First, the reviewers assessed titles and abstracts to exclude irrelevant literature; they then consulted the full texts of presumably relevant articles and determined whether the studies were appropriate for inclusion criteria and exclusion criteria. The relevant data were extracted by at least two reviewers, using a pre-designed data extraction form. Disagreements were resolved by discussion; when necessary, a third researcher was consulted to achieve consensus.

Evidence evaluation

The AGREE-II tool was used to evaluate the methodological quality of the relevant guidelines. The AMSTAR2 scale was used to evaluate the methodological quality of included systematic reviews. High quality systematic review and/or meta-analysis was used directly and it would be updated if the study had published for more than 2 years, among which Chinese children’s evidence was also collected and evaluated. The Cochrane Risk of Bias tool was used to evaluate the risk of bias of included RCTs. The Quality Assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of included diagnostic tests. The Newcastle-Ottawa scale was used to evaluate the methodological quality of included cohort and case-control studies. The evaluation process was completed by two independent reviewers; disagreements were resolved by discussion or consultation with a third reviewer to achieve consensus.

Quality evaluation of the evidence body was conducted based on the GRADE System in evidence summary of each clinical question (Table 3). The quality of evidence was graded as high, moderate, low, or very low; the strength of commendation was considered strong or weak (http://www.gradeworkinggroup.org/). The evidence was downgraded according to five criteria (i.e., risk of bias, inconsistency, indirectness, imprecision, and publication bias) or upgraded according to three criteria (i.e., large magnitude of effect, dose-response gradient, or plausible confounding can increase confidence in estimated effects). Evidence was presented through a summary of finding tables and evidence profiles.

Formulation of recommendation

The guideline development working group established 27 recommendations based on the systematic review evidence related to each clinical question and the systematic review evidence developed by the guideline development working group. Recommendations on individual issues are combined relevant guideline evidence; the preferences and values of Chinese children and their guardians; the cost of intervention; and other advantages and disadvantages. Through three rounds of Delphi surveys and a face-to-face expert consensus meeting held in Beijing, China, on August 25, 2019, a total of 82 suggestions were collected and 24 final recommendations were formed. During this period, the guideline working group discussed and finalized all recommendations and quality of evidence grades.

Draft external review of the guideline

The guideline was reviewed by seven external peer

| Number | Searching strategy |
|--------|--------------------|
| #1     | “Snoring”[Mesh]    |
| #2     | “Sleep Apnea Syndromes”[Mesh:NoExp] |
| #3     | “Sleep Apnea, Obstructive”[Mesh] |
| #4     | ((sleep* AND (apnea* OR apnoea* OR hypopna* OR obstruct*OR disorder* OR disturb*)) OR snore* OR snoring*)) |
| #5     | #1 OR #2 OR #3 OR #4 |
| #6     | “Infant”[Mesh] |
| #7     | “Child, Preschool”[Mesh] |
| #8     | “Child”[Mesh] |
| #9     | “Adolescent”[Mesh] |
| #10    | (child*[Title/Abstract] OR pediat*[Title/Abstract] OR paediart*[Title/Abstract] OR infant*[Title/Abstract] OR infan*[Title/Abstract] OR youth*[Title/Abstract] OR toddler*[Title/Abstract] OR adolesec*[Title/Abstract] OR teen*[Title/Abstract] OR boy*[Title/Abstract] OR girl*[Title/Abstract] OR bab*[Title/Abstract] OR preschool*[Title/Abstract] OR pre-school*[Title/Abstract]) |
| #11    | #6 OR #7 OR #8 OR #9 OR #10 |
| #12    | #5 AND #11 |
| #13    | “Meta-Analysis” [Publication Type] |
| #14    | “Meta-Analysis as Topic”[Mesh] |
| #15    | Meta analysis |
| #16    | Meta analyses |
| #17    | Systematic review |
| #18    | Systematic reviews |
| #19    | OR/13–18 |
| #20    | #12 AND #19 |
experts and improved on the basis of their feedback and suggestions. Finally, the guideline development working group submitted the guideline to the steering group for approval.

**Dissemination and implementation of this guideline**

The guideline was disseminated and promoted in the following ways: 1) Introduction and interpretation in relevant academic conferences; 2) Presentation at gatherings of otorhinolaryngologists, respiratory physicians, sleep monitoring technicians, nurses, and other relevant medical workers throughout China to learn the relevant contents of the guideline and use it correctly; 3) Dissemination through the Internet.

Estimation of advantageous and disadvantageous factors that may affect implementation of the guideline. Advantageous factors: snoring and sleep apnea are gradually recognized by the public, parents closely monitor their children’s sleep problems, and clinicians at all levels strongly demand pediatric OSA-related guideline. Disadvantageous factors: 1) OSA is a type of sleep disorder for which the main clinical manifestations are snoring and sleep apnea. Sleep disorders cover a wide range, and now tend to require combined diagnosis and treatment by clinicians in otorhinolaryngology, head and neck surgery, respiratory, stomatology, and developmental behavior specialties. This guideline mainly focus on OSA in children with enlarged tonsils, adenoids, and/or obesity; however, they do not consider primary snoring, central apnea or hypopnea syndrome, and other congenital or severe diseases. 2) The study population for which evidence was obtained in this guideline rarely included 14–18-year-old children/adolescents. The growth and development of older children/adolescents is similar to that of adults, but is quite different from that of young children. Therefore, older children/adolescents exhibit adult morbidity characteristics; they can be treated in accordance with the principles of diagnosis and treatment for adult OSA. 3) This guideline aimed to address the efficacy and safety of leukotriene receptor antagonists in the treatment of pediatric OSA. Montelukast sodium was the main focus of the available clinical evidence, as there was no evidence regarding other leukotriene receptor antagonists.

**Updates of the guideline**

The preparation team plans to update this guideline 3–5 years after their publication. The update method will be implemented in accordance with the international guidelines update process.

**Version statement**

There are two versions of this guide, Chinese and English. The Chinese version of this guideline will be jointly published by the *Chinese Journal of Otorhinolaryngology* and the *Chinese Journal of Evidence-based Medicine*, while the English version will be jointly published by *Pediatric Investigation* and *World Journal of Otorhinolaryngology-Head and Neck Surgery*. The supporting data of the guideline are stored in the National Center for Children’s Health/Beijing Children’s Hospital, Capital Medical University.

**Expert who draft the guideline:** Xin Ni (Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health)

**The steering group:** Zhiqiang Gao (Chinese Academy of Medical Sciences & Peking Union Medical College Hospital), Demin Han (Beijing Tongren Hospital, Capital Medical University), Xin Ni (Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Chen Wang (Chinese Academy of Medical Sciences), Qiang Wang (National Health Commission of the People’s Republic of China), Junmin Wei (Chinese Medical Journals Publishing House), Hao Wu (Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine), Kehu Yang (Chinese GRADE Center, Evidence-based Medicine Center, Lanzhou University), Siyan Zhan (Evidence-based Medicine Center, Peking University/School of Public Health, Peking University)

**The guideline development group:** Xiaohong Cai (Department of Pediatric Sleep Medicine, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University), Ling Cao (Department of Respiratory Medicine, Children’s Hospital Affiliated to Capital Institute of Pediatrics), Jie Chen (Department of Otorhinolaryngology, Head and Neck Surgery, Children’s Medical Center Affiliated to Shanghai Jiao Tong University, National Center for Children’s Health), Bobei Chen (Department of Otorhinolaryngology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University), Yaolong Chen (Chinese GRADE Center, Institute of Health Data Science, Lanzhou University), Xuemei Gao (Department of Orthodontics, Peking University School and Hospital of Stomatology), Wentong Ge (Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Fang Han (Department of Respiratory Medicine, Peking University People’s Hospital), Yan Huang (Department of Respiratory Medicine, Savaid Medical School, University of Chinese Academy of Sciences), Fan Jiang (Department of Developmental Behavioral Pediatrics, Shanghai Children’s Medical Center affiliated to Shanghai Jiao Tong University, National Center for Children’s Health), Lan Li (Department of Otorhinolaryngology, Head and Neck Surgery, Shenzhen Children’s Hospital), Dabo Liu (Department of Pediatrics Otorhinolaryngology, Shenzhen Hospital of Southern Medical University), Xiaofeng Lu (Department of Stomatology and Craniofacial Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine), Jie Mi (Chronic Disease Management Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Xiaohong Cai (Department of Otorhinolaryngology, Head and Neck Surgery and the Chinese Journal of Otorhinolaryngology, Department of Otorhinolaryngology, Head and Neck Surgery, Shanghai Jiao Tong University School of Medicine), Jie Chen (Department of Otorhinolaryngology, Head and Neck Surgery, Shenzhen Children’s Hospital), Demin Han (Beijing Tongren Hospital, Capital Medical University).
The evidence synthesis and evaluation group: Jiangnan Du (Department of Pediatric Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Xiaolian Fang (Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Tingting Ji (Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Jianrong Li (Evidence-based Medicine Center, Peking University/School of Public Health, Peking University), Kun Li (Clinical Epidemiology and evidence-based Medicine Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Xiaodan Li (Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Yali Liu (Clinical Epidemiology and Evidence-based Medicine Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Yuwei Liu (Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Tiesong Zhang (Department of Lanzhou University School and Hospital of Stomatology), Tiesong Zhang (Department of Orthodontics, Peking University), Xianglong Zeng (Department of Orthodontics, Peking University), Wen Xu (Department of Otorhinolaryngology, head and neck surgery, Beijing Tongren Hospital, Capital Medical University), Xinghua Yang (Department of Otorhinolaryngology, Head and Neck Surgery, Children’s Hospital of Chongqing Medical University), Qingyun Li (Department of Respiratory Medicine, Shengjing Hospital of China Medical University), Yunxiao Shang (Department of Pediatric Respiratory Medicine, Shengjing Hospital of China Medical University), Libin Zhang (Clinical Epidemiology and evidence-based Medicine Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Zehao Wu (Clinical Epidemiology and evidence-based Medicine Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Hui Yan (Children’s Hospital Affiliated to Zhengzhou University), Qi Zhou (The First Clinical Medicine College of Lanzhou University).

The external review group: Yanyi Jin (Center for Evidence-Based Medicine, Capital Medical University, National Center for Children’s Health), Qin Li (Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Zhaoyi Wu (Clinical Epidemiology and evidence-based Medicine Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health), Jinfeng Sun (Children’s Hospital Affiliated to Zhengzhou University), Qi Zhou (The First Clinical Medicine College of Lanzhou University).

CONFLICT OF INTEREST

None.

REFERENCES

1. Editorial Board of Chinese Journal of Otorhinolaryngology. Diagnosis and treatment of pediatric sleep apnea hypopnea syndrome (Urumqi). Chin J Otorhinolaryngol Head Neck Surg. 2007;42:83-84. (in Chinese).
2. Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130:e1142-755.
3. Li AM, So HK, Au CT, Ho C, Lau J, Ng SK, et al. Epidemiology of obstructive sleep apnea syndrome in Chinese children: a two-phase community study. Thorax. 2010;65:991-997.
4. Tan HL, Gozal D, Kheirandish-Gozal L. Obstructive sleep apnea in children: a critical update. Nat Sci Sleep. 2013;5:109-123.
5. Chan KC, Au CT, Hui LL, Wing YK, Li AM. Childhood OSA is an independent determinant of blood pressure in adulthood: longitudinal follow-up study. Thorax. 2020;75:422-431.
6. Tseng PH, Lee PL, Hsu WC, Ma Y, Lee YC, Chiu HM, et al. A higher proportion of metabolic syndrome in Chinese subjects with sleep-disordered breathing: A case-control study based on electrocardiogram-derived sleep analysis. PLoS One. 2017;12:e0169394.
7. Shen Y, Xu Z, Shen K. Urinary leukotriene E4, obesity, and adenotonsillar hypertrophy in Chinese children with sleep disordered breathing. Sleep. 2011;34:1135-1141.
8. Kadiotis AG, Alonso Alvarez ML, Boudewyns A, Alexopoulos EI, Erus R, Joosten K, et al. Obstructive sleep...
10. Section on Pediatric Pulmonology, Subcommittee on Obstructive Sleep Apnea Syndrome. American Academy of Pediatrics. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatr Pulmonol. 2002;33:239-253.

11. Materia E, Baglio G, Bellussi L, Marchisio P, Perletti L, Pallestrini E, et al. The clinical and organisational appropriateness of tonsillectomy and adenoidectomy—an Italian perspective. Int J Pediatr Otorhinolaryngol. 2005;69:497-500.

12. Roland PS, Rosenfeld RM, Brooks LJ, Friedman NR, Jones J, Kim TW, et al. Clinical practice guideline: Polysomnography for sleep-disordered breathing prior to tonsillectomy in children. Otolaryngol Head Neck Surg. 2011;145:S1-S15.

13. Villa Asensi JR, Martínez Carrasco C, Pérez Pérez G, Cortell Aznar I, Gómez-Pastrana D, Alvarez Gil D, et al. Guidelines for the diagnosis and management of sleep apnea-hypopnea syndrome in children. An Pediatr (Barc). 2006;65:364-376.

14. Berry RB, Albertario CL, Harding SM, Lloyd RM, Plante DT, Quan SF, et al. For the American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Version 2.5. Darien, IL: American Academy of Sleep Medicine; 2018.

15. Brietzke SE, Katz ES, Roberson DW. Can history and physical examination reliably diagnose pediatric obstructive sleep apnea/hypopnea syndrome? A systematic review of the literature. Otolaryngol Head Neck Surg. 2004;131:827-832.

16. Cerval V, Catumbela E, Winck JC, Azevedo I, Teixeira-Pinto A, Costa-Pereira A. Clinical assessment of pediatric obstructive sleep apnea: a systematic review and meta-analysis. Laryngoscope. 2012;122:2105-2114.

17. De Luca Canto G, Singh V, Major MP, Witmans M, El-Hakim H, Major PW, et al. Diagnostic capability of questionnaires and clinical examinations to assess sleep-disordered breathing in children: a systematic review and meta-analysis. J Am Dent Assoc. 2014;145:165-178.

18. Xu ZF, Wu YX, Feng GS, Zhang YM, Ni X. Evaluation of polysomnographic diagnostic criteria for obstructive sleep apnea syndrome in children. Chin J Otorhinolaryngol Head Neck Surg. 2016;51:806-811. (in Chinese)

19. Deng JK, Zheng YJ, Yuan XW. Study on polysomnography in differential diagnosis of snoring children. Biomed Eng Clin Med. 2005;9:220-221. (in Chinese)

20. Wang G, Xu Z, Tai J, Li X, Wu Y, Zhang Y, et al. Normative values of polysomnographic parameters in Chinese children and adolescents: a cross-sectional study. Sleep Med. 2016;27-28:49-53.

21. Kaditis AG, Alonso Alvarez ML, Bouwewyns A, Abel F, Alexopoulus El, Ersu R, et al. ERS statement on obstructive sleep disordered breathing in 1- to 23-month-old children. Eur Respir J. 2017;50:1700985.

22. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146:1387-1394.

23. Paediatric Sleep Medicine Clinical Network. New Zealand guidelines for the assessment of sleep-disordered breathing in childhood. https://www.ashm foundation.org.nz/assets/documents/New-Zealand-guidelines-for-the-assessment-of-sleep-disordered-breathing-in-childhood.pdf. Accessed May 1, 2020.

24. American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology. 2014;120:268-286.

25. Nolan J, Brietzke SE. Systematic review of pediatric tonsil size and polysomnogram-measured obstructive sleep apnea severity. Otolaryngol Head Neck Surg. 2011;144:844-850.

26. Mitchell RB, Garetz S, Moore RH, Rosen CL, Marcus CL, Katz ES, et al. The use of clinical parameters to predict obstructive sleep apnea syndrome severity in children: the Childhood Adenotonsillectomy (CHAT) study randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2015;141:130-136.

27. Leitzen KP, Brietzke SE, Lindsay RW. Correlation between nasal anatomy and objective obstructive sleep apnea severity. Otolaryngol Head Neck Surg. 2014;150:325-331.

28. Leonardis RL, Robison JG, Otteson TD. Evaluating the management of obstructive sleep apnea in neonates and infants. JAMA Otolaryngol Head Neck Surg. 2013;139:139-146.

29. Katz ES, Mitchell RB, D’Ambrosio CM. Obstructive sleep apnea in infants. Am J Respir Crit Care Med. 2012;185:805-816.

30. Goroz A, Sagy M, Sagy N, Bock K. Severity assessment of obstructive sleep apnea syndrome (OSAS) in pediatric patients. Clin Pediatr (Phil). 2009;48:528-533.

31. Brockmann PE, Schaefer C, Poets A, Poets CF, Urschitz MS. Diagnosis of obstructive sleep apnea in children: a systematic review. Sleep Med Rev. 2013;17:331-340.

32. Nixon GM, Kermack AS, Davis GM, Manoukian JJ, Brown KA, Brouillette RT. Planning adenotonsillectomy in children with obstructive sleep apnea: the role of overnight oximetry. Pediatrics. 2004;113:e19-25.

33. Brouillette RT, Morrelli A, Leimanis A, Waters KA, Luciano R, Ducharme FM. Nocturnal pulse oximetry as an abbreviated testing modality for pediatric obstructive sleep apnea. Pediatrics. 2000;105:405-412.

34. Spruyt K, Gozal D. Pediatric sleep questionnaires as diagnostic or epidemiological tools: a review of currently available instruments. Sleep Med Rev. 2011;15:19-32.

35. Cerval V, de Lima FF, Winck JC, Azevedo I, Teixeira-Pinto A, Costa-Pereira A. Translation and cross-cultural adaptation of the Pediatric Sleep Questionnaire into Portuguese language. Int J Pediatr Otorhinolaryngol. 2015;79:175-178.

36. Bertran K, Mesa T, Rosso K, Krakowiak MJ, Pincheira A, Pinto A, Costa-Pereira A. Pediatric sleep questionnaires as diagnostic or epidemiological tools: a review of currently available instruments. Sleep Med Rev. 2011;15:19-32.

37. Wang CH, Yang CM, Huang YS. The validation and reliability of Chinese version of the Pediatric Sleep Questionnaire for screening of obstructive sleep apnea in habitually snoring children. Sleep Med. 2015;16:631-636.

38. Wang CH, Yang CM, Huang YS. The validation and reliability of Chinese version of the Pediatric Sleep Questionnaire for patients with sleep breathing problem.
Taiwan J Psychiatry (Taipei). 2012;26:177-186.

38. Li XD, Tai J, Xu ZF, Peng XX, Feng GS, Zhang YM, et al. The validity and reliability of simplified Chinese version of the pediatric sleep questionnaire for screening children with obstructive sleep apnea syndrome in Beijing. Chin J Otorhinolaryngol Head Neck Surg. 2016;51:812-818. (in Chinese)

39. Brodsky L. Modern assessment of tonsils and adenoids. Pediatr Clin North Am. 1989;36:1551-1569.

40. Franco RA Jr, Rosenfeld RM, Rao M. First place--resident clinical science award 1999. Quality of life for children with obstructive sleep apnea. Otolaryngol Head Neck Surg. 2000;123:9-16.

41. Lee CH, Hsu WC, Chang WH, Lin MT, Kang KT. Polysomnographic findings after adenotonsillectomy for obstructive sleep apnoea in obese and non-obese children: a systematic review and meta-analysis. Clin Otolaryngol. 2016;41:498-510.

42. Akkari M, Marianowski R, Chalumeau F, Fayoux P, Louboulanger N, Monteyrol PJ, et al. French Society of Otorhinolaryngology and Head and Neck Surgery (SFORL) guidelines concerning the role of otorhinolaryngologists in the management of paediatric obstructive sleep apnoea syndrome: Follow-up protocol for treated children. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135:427-431.

43. Mitchell RB, Archer SM, Ishman SL, Rosenfeld RM, Coles S, Finestone SA, et al. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngol Head Neck Surg. 2019;160:S1-S42.

44. Baugh RF, Archer SM, Mitchell RB, Rosenfeld RM, Amin R, Burns JJ, et al. Clinical practice guideline: tonsillectomy in children. Otolaryngol Head Neck Surg. 2011;144:S1-30.

45. Ji T, Lu T, Qiu Y, Li X, Liu Y, Tai J, et al. The efficacy and safety of mandibular advancement appliances for the treatment of obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med. 2021;78:193-201.

46. Kuhle S, Urschitz MS. Anti-inflammatory medications for obstructive sleep apnea in children. Cochrane Database Syst Rev. 2011;CD007074.

47. Chen X, Li J. Meta-analysis of nasal corticosteroid treatment in the children with obstructive sleep apnea hypopnea syndrome. J Otolaryngol Ophthalmol Shandong Univ. 2015;29:9-11. (in Chinese)

48. Ma D, Xu P. Montelukast sodium in light sleep-disordered breathing: A meta-analysis in children. Chin Gen Pract. 2013;16:3828-3832. (in Chinese)

49. Liming BJ, Ryan M, Mack D, Ahmad I, Camacho M. Montelukast and Nasal Corticosteroids to Treat Pediatric Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2019;160:594-602.

50. Zhang J, Chen J, Yin Y, Zhang L, Zhang H. Therapeutic effects of different drugs on obstructive sleep apnea/hypopnea in children. World J Pediatr. 2017;13:537-543.

51. Katherine Claridge MM. Neuropsychiatric events with the use of montelukast in pediatric patients. FDA Joint Meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees. U.S. Food and Drug Administration. 2019.

52. Pateron B, Marianowski R, Monteyrol PJ, Coulignon V, Akkari M, Chalumeau F, et al. French Society of ENT and Head & Neck Surgery (SFORL) guidelines (short version) on the roles of the various treatment options in childhood obstructive sleep apnea-hypopnea syndrome. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135:265-268.

53. Sleep Medicine Group of Respiratory Subsociety, Chinese Pediatric Society, Chinese Medical Association, Editorial Board of Chinese Journal of Applied Clinical Pediatrics. Consensus for non-invasive positive pressure ventilation in children with obstructive sleep apnoea hypopnea syndrome (draft). Chin J Appl Clin Pediatr. 2016;31:1451-1455. (in Chinese)

54. Camacho M, Chang ET, Song SA, Abdullatif J, Zaghni S, Pirelli P, et al. Rapid maxillary expansion for pediatric obstructive sleep apnea: A systematic review and meta-analysis. Laryngoscope. 2017;127:1712-1719.

55. Machado-Júnior AJ, Zancanella E, Crespo AN. Rapid maxillary expansion and obstructive sleep apnea: a review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2016;21:e465-469.

56. Vale F, Albergaria M, Carrilho E, Francisco I, Guimarães A, Caramelo F, et al. Efficacy of rapid maxillary expansion in the treatment of obstructive sleep apnea syndrome: A systematic review with meta-analysis. J Evid Based Dent Pract. 2017;17:159-168.

57. Seif-Eldin NF, Elkordy SA, Fayed MS, Elbeialy AR, Eid FH. Transverse skeletal effects of rapid maxillary expansion in pre and post pubertal subjects: A systematic review. Open Access Maded J Med Sci. 2019;7:467-477.

58. Carvalho FR, Lentinii-Oliveira DA, Prado LB, Prado GF, Carvalho LB. Oral appliances and functional orthopaedic appliances for obstructive sleep apnoea in children. Cochrane Database Syst Rev. 2016;10:CD005520.

59. Yanyan M, Min Y, Xuemei G. Mandibular advancement appliances for the treatment of obstructive sleep apnea in children: a systematic review and meta-analysis. Sleep Med. 2019;60:145-151.

60. Andersen IG, Holm JC, Homoe P. Obstructive sleep apnea in obese children and adolescents, treatment methods and outcome of treatment - a systematic review. Int J Pediatr Otorhinolaryngol. 2016;87:190-197.

61. Roche J, Gillert V, Perret F, Mougin F. Obstructive sleep apnea and sleep architecture in adolescents with severe obesity: effects of a 9-month lifestyle modification program based on regular exercise and a balanced diet. J Clin Sleep Med. 2018;14:967-976.

62. National Health and Family Planning Commission of the People's Republic of China. Health industry standard of the People's Republic of China (WS/T 586-2018). Screening of overweight and obesity among school-age children and adolescents. http://www.nssi.org.cn/nssi/front/108442010.html. Accessed March 1, 2020.

63. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102:709-757.

64. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.

65. World Health Organization. WHO handbook for guideline development-2nd ed. World Health Organization.2014. https://apps.who.int/iris/handle/10665/145714. Accessed March 1, 2020.

66. Brouwers MC, Kho ME, Brown GP, Burgers JS.
Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308-1311.

67. Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement. Ann Intern Med. 2017;166:128-132.

68. Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health; Otorhinolaryngology Head and Neck Surgery Branch of Chinese Medical Association; Pediatric surgery Branch of Chinese Medical Association; Pediatric Branch of Chinese Medical Association; Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery. Chinese guideline for the diagnosis and treatment of childhood obstructive sleep apnea: a protocol. Chin J Evid Based Med. 2020;20:102-107. (in Chinese)

69. Tao H, Yang L, Ping A, Quan L, Yang X, Zhang Y, et al. Interpretation of AMSTAR 2: a critical appraisal tool for systematic reviews that include randomized or non-randomized studies of healthcare interventions. Chin J Evid Based Med. 2018;18:101-108. (in Chinese)

How to cite this article: Working group of Chinese guideline for the diagnosis and treatment of childhood OSA; Subspecialty Group of Pediatrics, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association; Subspecialty Group of Respiratory Diseases, Society of Pediatrics, Chinese Medical Association; Society of Pediatric Surgery, Chinese Medical Association; Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery. Chinese guideline for the diagnosis and treatment of childhood obstructive sleep apnea (2020). Pediatr Investig. 2021;5:167-187. https://doi.org/10.1002/ped4.12284